Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy

Vadevoo, Sri Murugan Poongkavithai; Gurung, Smriti; Khan, Fatima; Haque, Md. Enamul; Gunassekaran, Gowri Rangaswamy; Chi, Lianhua; Permpoon, Uttapol; Lee, Byungheon

doi:10.1007/s12272-019-01125-0

Cited by 30 publications

(23 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the aforementioned therapeutic peptides, peptides with specific cancer cell targets are applied to bind the cancer cell targets for cancer detection and therapy (216,217). For example, a sodium pump Na + /K + ATPase α1-targeted peptide for positron emission tomography imaging of breast cancer, as peptide-based platform on dual-targeted molecular imaging, is able to more obviously visualize the disease state of a patient, leading to improved informed treatment decisions (218,219).…”

Section: Future Directionmentioning

confidence: 99%

“…ACP construction for specific cancer cell targets, and predictive, preventive and personalized medicine may be beneficial to the cancer research field due to the different complexity of the whole-body system in each individual ( 215 ). Besides the aforementioned therapeutic peptides, peptides with specific cancer cell targets are applied to bind the cancer cell targets for cancer detection and therapy ( 216 , 217 ). For example, a sodium pump Na + /K + ATPase α1-targeted peptide for positron emission tomography imaging of breast cancer, as peptide-based platform on dual-targeted molecular imaging, is able to more obviously visualize the disease state of a patient, leading to improved informed treatment decisions ( 218 , 219 ).…”

Section: Future Directionmentioning

confidence: 99%

See 1 more Smart Citation

Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)

2020

View full text Add to dashboard Cite

Cancer is currently ineffectively treated using therapeutic drugs, and is also able to resist drug action, resulting in increased side effects following drug treatment. A novel therapeutic strategy against cancer cells is the use of anticancer peptides (ACPs). The physicochemical properties, amino acid composition and the addition of chemical groups on the ACP sequence influences their conformation, net charge and orientation of the secondary structure, leading to an effect on targeting specificity and ACP-cell interaction, as well as peptide penetrating capability, stability and efficacy. ACPs have been developed from both naturally occurring and modified peptides by substituting neutral or anionic amino acid residues with cationic amino acid residues, or by adding a chemical group. The modified peptides lead to an increase in the effectiveness of cancer therapy. Due to this effectiveness, ACPs have recently been improved to form drugs and vaccines, which have sequentially been evaluated in various phases of clinical trials. The development of the ACPs remains focused on generating newly modified ACPs for clinical application in order to decrease the incidence of new cancer cases and decrease the mortality rate. The present review could further facilitate the design of ACPs and increase efficacious ACP therapy in the near future.

show abstract

Section: Future Directionmentioning

confidence: 99%

Section: Future Directionmentioning

confidence: 99%

Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)

2020

View full text Add to dashboard Cite

show abstract

“…PDCs are therefore promising candidates for personalized cancer treatments. [1][2][3] Daunorubicin (Dau) is an anthracycline anticancer drug used for the treatment of a variety of cancers including varying type of leukaemia. Daunorubicin was used for the development of a large number of peptide-drug conjugates in our laboratory that showed efficient antitumor activity not only in vitro, but also in vivo.…”

mentioning

confidence: 99%

Energy‐resolved HCD fragmentation of daunorubicin‐peptide conjugates

et al. 2020

View full text Add to dashboard Cite

“…10 -12 Moreover, by conjugated with various ligands, drugs could actively target to AML cell-surface receptors, which may have a tremendous improvement in treatment response or overall survival (OS) rates. 13,14…”

Section: Introductionmentioning

confidence: 99%

“…[10][11][12] Moreover, by conjugated with various ligands, drugs could actively target to AML cell-surface receptors, which may have a tremendous improvement in treatment response or overall survival (OS) rates. 13,14 This review attempts to present an overview of nanomedicines for AML currently in experimental researches or clinical trials from published data, with a focus on targeting ligands. This article may not be exhaustive due to the rapid development of new drugs.…”

Section: Introductionmentioning

confidence: 99%

Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

et al. 2019

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a hematological malignancy, which is commonly associated with high incidence and mortality among adult patients. The standard induction regimen for AML has been substantially unchanged over the past 40 years, for which novel nanomedicines have represented a promising strategy in AML therapies. Despite developments of multiple nanoparticles formulated with drugs or genes, less there is not much information available about approaches in AML is available. This review presents an overview of nanomedicines currently being evaluated in AML. First, it briefly summarized conventional chemotherapies in use. Second, nanomedicines presently ongoing in clinical trials or preclinical researches were classified and described, with illustrative examples from recent literatures. Finally, limitations and potential safety issues concerns in clinical translation of AML treatment were discussed as well.

show abstract

Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy

Cited by 30 publications

References 65 publications

Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)

Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)

Energy‐resolved HCD fragmentation of daunorubicin‐peptide conjugates

Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

Contact Info

Product

Resources

About